J&J Drops Erleada-Zytiga Prostate Cancer Combination

Johnson & Johnson (J&J) will not be seeking regulatory approval for its prostate cancer combination treatment following disappointing phase 3 study results.

In the 982-person trial, the combination of Erleada (apalutamide) plus Zytiga (abiraterone acetate) met its primary endpoint of progression-free survival but failed to show significant benefit over Zytiga plus prednisone, the drugmaker said.

However, the study generated valuable insights in subgroups of patients that could warrant further investigation, said Kiran Patel, a vice president of clinical development at J&J’s Janssen subsidiary.